Phase 3 Trials of Solanezumab and Bapineuzumab for Alzheimer's Disease
Year: 2014
Type: letter
Source: New England Journal of Medicine
DOI: 10.1056/nejmc1402193
Author: Christoph Laske
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: closed
Funder: National Institute on Aging
OpenAlex ID: W1268992491
